Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.
Trends Mol Med. 2011 Jun;17(6):313-9. doi: 10.1016/j.molmed.2011.01.006. Epub 2011 Mar 2.
Recognition that breast cancer is a heterogeneous disease in which each patient's tumor has specific characteristics has led to a search for biomarkers and combinations of markers (signatures) to improve the diagnosis, prognostic classification and prediction of therapeutic benefit versus toxicity for individual tumors and patients. Many microRNAs (miRNAs) are aberrantly expressed in cancer and seem to influence tumor behavior and progression. miRNAs have great potential to evolve into effective biomarkers in the clinic because of their extreme stability and ease of detection. However, there are several major technical challenges as well as numerous discrepancies among currently reported miRNA signatures. In this review, we discuss the use of miRNA signatures for breast cancer treatment and discuss the challenges in the field.
认识到乳腺癌是一种异质性疾病，每个患者的肿瘤都具有特定的特征，这导致了对生物标志物和标记物组合（特征）的研究，以改善对个体肿瘤和患者的诊断、预后分类以及治疗获益与毒性的预测。许多 microRNAs（miRNAs）在癌症中表达异常，似乎影响肿瘤的行为和进展。由于 miRNA 极其稳定且易于检测，因此它们具有成为临床有效生物标志物的巨大潜力。然而，目前报道的 miRNA 特征之间存在许多主要的技术挑战和差异。在这篇综述中，我们讨论了 miRNA 特征在乳腺癌治疗中的应用，并讨论了该领域的挑战。
